Drug Trial Radar · NCT06743438
Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB
Last checked: Nov 20, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
640
Actual
Start
Mar 10, 2022
Primary completion
Jun 30, 2024
Study completion Sep 30, 2029
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Tenofovir amibufenamide (TMF) is a novel prodrug of tenofovir that has been widely used in mainland China for the treatment of chronic hepatitis B (CHB). The previous registrational study (NCT03903796) has established the non-inferior virologic efficacy of TMF to tenofovir disoproxil fumarate (TDF), while demonstrating higher rates of alanine aminotransferase (ALT) normalization and improved bone and renal safety profiles. This study presented the long-term efficacy and safety of TMF in a phase IV study.
Conditions
- Hepatitis B, Chronic
Interventions
Tenofovir Amibufenamide(TMF)Drug
Once-daily oral dose of 25 mg TMF were maintained in all participants
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation the percentage of Participants with Hepatitis B Virus (HBV) DNA lower than in the central laboratoryTime frame: week (144+)96
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.